Long-Term and Concentration-Dependent Beneficial Effect of Efavirenz on HDL-Cholesterol in HIV-Infected Patients

Pereira, SA; Branco, T; Côrte-Real, R; Germano, I; Lampreia, F; Caixas, U; Monteiro, E

http://hdl.handle.net/10400.17/1777

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
BJCP 2006 601.pdf		123.96 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

AIMS: To investigate the long-term effects of efavirenz on cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C) and triglycerides (TG). METHODS: Thirty-four HIV-infected patients who commenced efavirenz therapy were monitored for 36 months. RESULTS: In patients with baseline HDL-C<40 mg.dL-1 an increase in HDL-C from 31+/-1 mg.dL-1 to 44+/-2 mg.dL-1 (95% confidence interval 5.9, 21.9, P<0.01) was observed and remained throughout the follow-up period. Median efavirenz plasma concentration was 1.98 mg.L-1 and a direct correlation between percentage of HDL-C variation or TC/HDL-C ratio and efavirenz plasma concentrations was found. CONCLUSIONS: There is evidence of a long-term and concentration-dependent beneficial effect of efavirenz on HDL-C in HIV-infected patients.

Keywords

CHLC MED Benzoxazinas Colesterol Colesterol HDL Relação Dose-Resposta a Medicamento Estudos de Follow-Up Glicoproteínas Infecção por HIV HIV-1 Oxazinas Estudos Prospectivos Inibidores de Transcriptase Reversa Factores de Tempo Resultado de Tratamento